70.15
0.88 (1.27%)
| Penutupan Terdahulu | 69.27 |
| Buka | 69.06 |
| Jumlah Dagangan | 1,292,937 |
| Purata Dagangan (3B) | 2,384,695 |
| Modal Pasaran | 9,524,306,944 |
| Harga / Jualan (P/S) | 80.43 |
| Harga / Buku (P/B) | 60.31 |
| Julat 52 Minggu |
| Margin Operasi (TTM) | -9,856.30% |
| EPS Cair (TTM) | -5.29 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 89.10% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 727.94% |
| Nisbah Semasa (MRQ) | 5.99 |
| Aliran Tunai Operasi (OCF TTM) | -398.00 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -241.41 M |
| Pulangan Atas Aset (ROA TTM) | -34.12% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Menaik | Bercampur |
| Biotechnology (Global) | Menaik | Bercampur | |
| Stok | Cytokinetics, Incorporated | Menurun | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | -2.0 |
| Aktiviti Orang Dalam | -2.5 |
| Volatiliti Harga | 2.0 |
| Purata Bergerak Teknikal | -2.5 |
| Osilator Teknikal | -0.5 |
| Purata | -1.10 |
|
Cytokinetics Inc is a late-stage biopharmaceutical company focused on discovering, developing, and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary disease. The company's product, named as MYQORZO, is an allosteric and reversible inhibitor of cardiac myosin motor activity. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Growth |
| % Dimiliki oleh Orang Dalam | 0.72% |
| % Dimiliki oleh Institusi | 119.58% |
Tiada data dalam julat masa ini.
| Nama | Purata Belian ($) | Purata Jualan ($) | Jumlah Net | Jumlah Nilai Bersih ($) |
|---|---|---|---|---|
| CALLOS ANDREW | - | 73.68 | -15,000 | -1,105,200 |
| KAYE EDWARD M. MD | - | 73.68 | -2,933 | -216,103 |
| MALIK FADY IBRAHAM | - | 68.45 | -3,500 | -239,575 |
| PARSHALL B LYNNE | - | 73.68 | -5,000 | -368,400 |
| Jumlah Keseluruhan Kuantiti Bersih | -26,433 | |||
| Jumlah Keseluruhan Nilai Bersih ($) | -1,929,278 | |||
| Purata Pembelian Keseluruhan ($) | - | |||
| Purata Jualan Keseluruhan ($) | 72.37 | |||
| Nama | Pemegang | Tarikh | Jenis | Kuantiti | Harga | Nilai ($) |
|---|---|---|---|---|---|---|
| MALIK FADY IBRAHAM | Pegawai | 09 Jun 2026 | Jual (-) | 3,500 | 68.45 | 239,575 |
| MALIK FADY IBRAHAM | Pegawai | 09 Jun 2026 | Pelaksanaan pilihan | 3,500 | - | - |
| PARSHALL B LYNNE | Pengarah | 01 Jun 2026 | Jual (-) | 5,000 | 73.68 | 368,400 |
| CALLOS ANDREW | Pegawai | 01 Jun 2026 | Jual (-) | 15,000 | 73.68 | 1,105,200 |
| CALLOS ANDREW | Pegawai | 01 Jun 2026 | Pelaksanaan pilihan | 15,000 | - | - |
| KAYE EDWARD M. MD | Pengarah | 01 Jun 2026 | Jual (-) | 2,933 | 73.68 | 216,103 |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |